Aubagio MS approval little to write home about

Date September 13, 2012

Aubagio has confirmed its status as one of the also-rans in the oral multiple sclerosis market following US approval yesterday that came with a black box warning for liver toxicity and the potential to cause birth defects.

It is this range of off-putting and serious side effects coupled with comparatively low efficacy that will almost certainly mean that little of the excitement surrounding other oral drugs in the space, in particular BG-12, will rub off onto Aubagio. It will also curtail sales in the US.

This content is written, edited and published by EP Vantage and is distributed by Evaluate Ltd. All queries regarding the content should be directed to: news@epvantage.com

EP Vantage is a unique, forward-looking, news analysis service tailored to the needs of pharma and finance professionals. EP Vantage focuses on the events that will define the future of companies, products and therapy areas, with detailed financial analysis of events in real-time, including regulatory decisions, product approvals, licensing deals, patent decisions, M&A.

Drawing on Evaluate, an industry-leading database of actual and forecast product sales and financials, EP Vantage gives readers the insight to make value-enhancing decisions.

EP Vantage SM ©2018 EP Vantage Ltd